Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | ACACA | Q13085 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270305 | 1.00 | OPRM1 (0.43) | OPRM1OPRL1OPRK1KMT2AACACB | |
| SCHEMBL3406561 | 1.00 | OPRM1 (0.43) | OPRM1OPRL1OPRK1KMT2AACACB | |
| SCHEMBL4344641 | 0.85 | OPRM1 (0.56) | OPRM1OPRL1OPRK1 | |
| SCHEMBL4344823 | 0.84 | OPRM1 (0.59) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3404628 | 0.81 | OPRM1 (0.45) | OPRM1OPRL1OPRK1ACACBACACA | |
| SCHEMBL4425740 | 0.81 | CHRM1 (0.51) | OPRM1OPRL1ALDH1A1 | |
| SCHEMBL3405713 | 0.81 | CHRM1 (0.51) | OPRM1OPRL1ALDH1A1 | |
| SCHEMBL3410347 | 0.80 | OPRM1 (0.48) | OPRM1OPRL1OPRK1L3MBTL3 | |
| SCHEMBL3409660 | 0.80 | OPRM1 (0.43) | OPRM1OPRL1OPRK1HPGD | |
| SCHEMBL1928278 | 0.80 | OPRL1 (0.70) | OPRM1OPRL1OPRK1KMT2AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | CHRM1, CHRM2, CHRM3 | OPRM1 6/4885OPRL1 7/4885OPRK1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.